Drug Overview

ORLADEYO (berotralstat) is a first-in-class, small-molecule IMMUNOMODULATOR and a highly specific PLASMA KALLIKREIN INHIBITOR within the IMMUNOLOGY drug category. As a TARGETED THERAPY, it represents a significant shift in the management of Hereditary Angioedema (HAE) by offering the first once-daily oral option for long-term prevention.

Generic Name: Berotralstat
US Brand Name: Orladeyo
Drug Class: Plasma Kallikrein Inhibitor
Route of Administration: Oral (Capsules)
FDA Approval Status: FDA-approved for routine prophylaxis to prevent attacks of Hereditary Angioedema (HAE) in adults and pediatric patients 12 years of age and older.

Orladeyo is not intended for the acute treatment of an HAE attack. Instead, it is used as a daily maintenance medication to reduce the frequency and severity of the sudden, debilitating swelling episodes that characterize the condition.

What Is It and How Does It Work? (Mechanism of Action)

Molecular and Cellular Level Action

Orladeyo functions through SELECTIVE CYTOKINE INHIBITION and enzyme blockade:

Enzyme Inhibition: Berotralstat is a potent and selective inhibitor of plasma kallikrein.
Prevention of Cleavage: By binding to the active site of the kallikrein enzyme, Orladeyo prevents it from cleaving High-Molecular-Weight Kininogen (HMWK).
Bradykinin Suppression: This cleavage is the specific step that releases BRADYKININ, the inflammatory peptide responsible for increasing vascular permeability.
Vascular Stability: By lowering bradykinin production at the source, Orladeyo prevents the fluid from leaking out of blood vessels into surrounding tissues, thereby preventing the systemic inflammation and swelling associated with HAE.

FDA-Approved Clinical Indications

Primary Indication: Prophylaxis of Hereditary Angioedema (HAE)

Orladeyo is indicated for the routine prevention of HAE attacks in adults and adolescents aged 12 and older. It modulates the immune-driven inflammatory response by maintaining a steady-state level of kallikrein inhibition, effectively reducing the “attack burden” for the patient.

Other Approved & Off-Label Uses

While its primary indication is specific to HAE types I and II, research is ongoing in other vascular environments:

HAE with Normal C1-INH: Investigated in specialized clinical trials for patients with bradykinin-mediated angioedema who do not have a C1-inhibitor deficiency.
Acquired Angioedema (AAE): Explored as a potential oral alternative for patients with acquired forms of C1-INH deficiency.

Primary Immunology Indications

Maintenance of Vascular Integrity: Preventing the sudden “leakiness” of vessels by suppressing bradykinin.
Selective Immunomodulation: Targeting the plasma kallikrein enzyme without suppressing the broader immune system’s ability to fight infections.

Dosage and Administration Protocols

Orladeyo is administered as a once-daily oral capsule, which significantly improves quality of life compared to injectable prophylactic treatments.

Indication	Standard Dose	Frequency
HAE Prophylaxis (Adults/Adolescents ≥12y)	150 mg	Once Daily
Hepatic Impairment (Moderate to Severe)	110 mg	Once Daily
Drug Interactions (CYP3A4/P-gp inhibitors)	110 mg	Once Daily

Dose Adjustments and Special Populations

Hepatic Impairment: For patients with moderate or severe liver dysfunction (Child-Pugh Class B or C), the dose is reduced to 110 mg.
Renal Impairment: No dose adjustment is required for patients with mild, moderate, or severe renal impairment.
Drug-Drug Interactions: Berotralstat is a substrate of P-glycoprotein (P-gp) and CYP3A4. Dose reduction may be necessary when co-administered with certain inhibitors of these pathways (e.g., cyclosporine).

Clinical Efficacy and Research Results

The approval of Orladeyo was supported by the APeX-2 trial, which established its efficacy and safety profile through 2026.

Numerical Research Data

Attack Rate Reduction: In the APeX-2 study, patients on 150 mg once daily experienced a significant reduction in HAE attacks compared to placebo.
Sustained Response: Data through 48 weeks showed that patients achieved a significant and sustained reduction in attack frequency, with some patients seeing a greater than 70% reduction in attacks.
Quality of Life: Research demonstrated significant improvements in the Angioedema Quality of Life (AE-QoL) total score, particularly in the “functioning” and “fears/shame” domains.

Recent Research (2024–2026)

Current research in PRECISION IMMUNOLOGY focuses on “Long-Term Extension” studies. 2025 data suggests that the efficacy of Orladeyo actually improves over time as steady-state levels are maintained in the tissues. Additionally, studies are exploring the “Direct Clinical Connection” between berotralstat and the reduction of sub-clinical swelling, which can contribute to chronic fatigue in HAE patients.

Safety Profile and Side Effects

Orladeyo is generally well-tolerated, particularly because it is a TARGETED THERAPY that does not cause broad immunosuppression.

Common Side Effects (>10%)

Gastrointestinal Distress: Abdominal pain, vomiting, and diarrhea (most common during the first few weeks of therapy).
Back Pain: Reported by a subset of patients in clinical trials.
Headache: Usually mild and transient.

Serious Adverse Events

QT Prolongation: At doses higher than the recommended 150 mg, Orladeyo may cause a prolongation of the QT interval (a heart rhythm concern).
Severe Hypersensitivity: Rare cases of systemic allergic reactions.

Management Strategies

GI Management: Taking Orladeyo with a meal may help reduce initial gastrointestinal side effects.
Cardiac Monitoring: Avoid using Orladeyo with other medications known to prolong the QT interval.
Dose Adherence: Patients should be counseled not to take additional doses to “make up” for a missed dose, as this increases the risk of heart rhythm issues.

Research Areas

Direct Clinical Connections

Active research is exploring the CYTOKINE STORMS and vascular cascades. Scientists are investigating if plasma kallikrein inhibition can be utilized in other “capillary leak” syndromes where bradykinin drives life-threatening edema.

Generalization and Advancements

Pediatric Expansion: Research (2025–2026) is ongoing to evaluate the safety and efficacy of Orladeyo in children under the age of 12.
Precision Immunology: Using genetic markers to identify patients who are “hyper-responders” to berotralstat.
Biosimilars: While Orladeyo is a relatively new small molecule, the foundation for future BIOSIMILAR-equivalent inhibitors is being laid in global research labs.

Disclaimer: The research mentioned regarding the use of Orladeyo in children under 12, the identification of genetic markers for “hyper-responders,” and the exploration of kallikrein inhibition in systemic “capillary leak” syndromes is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Baseline Diagnostics: Confirmation of HAE Type I or II and baseline Liver Function Tests (LFTs).
EKG: Consider a baseline EKG for patients with pre-existing heart conditions or those on medications that affect the QT interval.
Drug Review: Comprehensive review of P-gp and CYP3A4 inhibitors.

Monitoring and Precautions

Vigilance: Patients should report any “racing heart” sensations or fainting spells (potential QT issues).
Symptom Tracking: Maintain an HAE attack diary to monitor the drug’s efficacy and the need for rescue medication.
Lifestyle:
- Dietary Consistency: Take the capsule at the same time every day with food to maintain steady blood levels and minimize GI upset.
- Stress Management: Identify and avoid emotional or physical triggers that may provoke breakthrough attacks.

Do’s and Don’ts

DO keep your rescue (on-demand) medication (e.g., icatibant or C1-INH) available at all times.
DO take the capsule whole; do not chew or open it.
DON’T take more than one 150 mg capsule in a 24-hour period.
DON’T stop the medication without consulting your immunologist, as this may lead to a sudden increase in attack frequency.

Legal Disclaimer

This guide is provided for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. The use of ORLADEYO (berotralstat) must be managed by a qualified specialist in immunology or allergy. Always consult with your healthcare professional regarding the risks and benefits of TARGETED THERAPY. Never disregard professional medical advice based on information provided in this guide.